Pharvaris (PHVS) Competitors $23.20 -0.30 (-1.28%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$23.22 +0.02 (+0.09%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. PTCT, KRYS, PCVX, ACAD, ACLX, ADMA, ARWR, MENS, MIRM, and MLTXShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals Jyong Biotech Mirum Pharmaceuticals MoonLake Immunotherapeutics Pharvaris (NASDAQ:PHVS) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends. Does the media favor PHVS or PTCT? In the previous week, PTC Therapeutics had 14 more articles in the media than Pharvaris. MarketBeat recorded 17 mentions for PTC Therapeutics and 3 mentions for Pharvaris. PTC Therapeutics' average media sentiment score of 1.00 beat Pharvaris' score of 0.98 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, PHVS or PTCT? Pharvaris has a beta of -2.8, meaning that its stock price is 380% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Is PHVS or PTCT more profitable? PTC Therapeutics has a net margin of 35.65% compared to Pharvaris' net margin of 0.00%. Pharvaris' return on equity of -69.09% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -69.09% -63.34% PTC Therapeutics 35.65%-106.31%30.61% Which has preferable valuation and earnings, PHVS or PTCT? Pharvaris has higher earnings, but lower revenue than PTC Therapeutics. Pharvaris is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$145.24M-$3.36-6.90PTC Therapeutics$806.78M6.02-$363.30M$6.978.76 Do analysts rate PHVS or PTCT? Pharvaris currently has a consensus target price of $34.00, indicating a potential upside of 46.55%. PTC Therapeutics has a consensus target price of $69.00, indicating a potential upside of 12.95%. Given Pharvaris' stronger consensus rating and higher possible upside, research analysts plainly believe Pharvaris is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53 SummaryPTC Therapeutics beats Pharvaris on 9 of the 13 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21B$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-6.9021.5775.5726.02Price / SalesN/A254.90461.9291.11Price / CashN/A44.4425.8129.91Price / Book4.199.6112.526.25Net Income-$145.24M-$53.29M$3.29B$270.76M7 Day Performance6.28%0.57%0.78%2.54%1 Month Performance4.04%4.56%4.56%5.73%1 Year Performance10.90%10.44%66.82%25.85% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris2.4902 of 5 stars$23.20-1.3%$34.00+46.6%+10.9%$1.21BN/A-6.9030PTCTPTC Therapeutics3.6583 of 5 stars$56.95-0.5%$69.00+21.2%+79.7%$4.55B$806.78M8.171,410Positive NewsKRYSKrystal Biotech4.9657 of 5 stars$145.20-3.4%$210.38+44.9%-28.7%$4.35B$290.52M29.51210Positive NewsPCVXVaxcyte2.3331 of 5 stars$32.41-1.8%$130.00+301.1%-72.3%$4.29BN/A-7.89160Positive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.376 of 5 stars$25.39+0.5%$28.88+13.7%+44.7%$4.26B$957.80M19.09510ACLXArcellx2.1052 of 5 stars$71.11-2.1%$114.31+60.7%-0.9%$4.03B$107.94M-20.7980Positive NewsADMAADMA Biologics3.6904 of 5 stars$16.42-2.7%$27.67+68.5%-10.9%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.1482 of 5 stars$27.17-6.6%$43.14+58.8%+38.3%$4.02B$3.55M-21.23400Analyst RevisionMENSJyong BiotechN/A$55.68+6.4%N/AN/A$3.98BN/A0.0031News CoverageGap DownHigh Trading VolumeMIRMMirum Pharmaceuticals3.3165 of 5 stars$77.39+1.7%$74.13-4.2%+80.7%$3.82B$336.89M-63.96140Analyst ForecastInsider TradeMLTXMoonLake Immunotherapeutics2.5028 of 5 stars$61.12+2.8%$74.43+21.8%+2.9%$3.82BN/A-21.992 Related Companies and Tools Related Companies PTC Therapeutics Alternatives Krystal Biotech Alternatives Vaxcyte Alternatives ACADIA Pharmaceuticals Alternatives Arcellx Alternatives ADMA Biologics Alternatives Arrowhead Pharmaceuticals Alternatives Jyong Biotech Alternatives Mirum Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHVS Stock Alerts